The UK government has published new guidance on veterinary medicine supply in Northern Ireland beyond 2025, setting out how products will continue to reach practices and farms in the region once current arrangements expire.

The guidance, released on GOV.UK, addresses a deadline that has shadowed Northern Ireland's veterinary sector since the region's post-Brexit trading position was settled: the grace period covering the supply of veterinary medicines from Great Britain to Northern Ireland. Without a negotiated solution, that provision was due to lapse, putting at risk the routine availability of animal health products — including vaccines, antiparasitics and anaesthetics — across the region's practices.

For veterinary surgeons in Northern Ireland, the stakes are concrete. The region sources the large majority of its veterinary medicines from Great Britain-based wholesalers. Any requirement to reroute supply through EU-approved channels, or to re-register products under EU rules, carried the prospect of withdrawal of medicines that have no EU marketing authorisation holder — a scenario the sector has warned could affect everything from routine companion-animal vaccination protocols to livestock herd health programmes.

The publication confirms the government's position that supply will continue beyond 2025, and directs stakeholders on the arrangements that apply once the current period ends. Practices, wholesalers and marketing authorisation holders operating in or supplying Northern Ireland should read the guidance in full, as responsibilities differ depending on role in the supply chain.

The companion-animal implication is straightforward: continued access to the full range of UK-authorised products keeps dispensing protocols unchanged. For food-animal practice, the continuity question is sharper — herd health plans on Northern Ireland's beef, dairy and sheep farms depend on reliable access to vaccines and antiparasitics delivered on schedule, and any supply disruption would carry direct productivity and animal welfare consequences.

There is also a public-health dimension. Northern Ireland's veterinarians deliver TB and notifiable disease controls under official programmes, and surveillance work depends on consistent access to diagnostics and medicines. Supply-chain fragmentation in that context is not a commercial inconvenience; it is an operational risk to disease control infrastructure.

Industry bodies including the National Office of Animal Health have previously warned that a cliff-edge in 2025 would have made a substantial share of the veterinary medicines market in Northern Ireland uneconomic to supply, given the region's relatively small volume compared with Great Britain. The government's guidance is the mechanism by which that outcome is now addressed.

Practices and suppliers should verify specific product questions against the guidance and with the Veterinary Medicines Directorate, which regulates UK-authorised veterinary medicines. Where a product's status in Northern Ireland is unclear — particularly for items authorised only in Great Britain — checking before placing standing orders will avoid gaps in dispensing and herd health calendars.

The guidance sits within the wider implementation of the Windsor Framework, the UK-EU arrangement governing Northern Ireland's trading relationships. How the arrangements perform in practice through 2026 and beyond — measured in product availability, delivery times and authorisation coverage — will determine whether the sector's supply concerns are resolved or merely deferred.